معرفی
Dr. Kathryn M. Ferguson is an Associate Professor of Pharmacology at Yale University School of Medicine and a member of the Yale Cancer Biology Institute. She holds roles as co-Director of Graduate Studies (co-DGS) in the Pharmacology Graduate Program and is affiliated with interdisciplinary teams such as the NIH-funded program studying membrane proteins in their natural environment. Her primary research focuses on the structural and mechanistic aspects of receptor tyrosine kinases (RTKs), particularly their roles in cancer and other diseases.
Dr. Ferguson earned her Ph.D. in Chemistry from Yale University (1996) and a BA in Physics from the University of Oxford (1987). After postdoctoral training at the University of Pennsylvania Perelman School of Medicine, she became faculty there before joining Yale in 2015. Her work spans structural biology, cryo-EM, and biochemical approaches to study RTK regulation, antibody therapies, and membrane environment effects on receptor function.
Research highlights include structural insights into EGFR variants linked to glioblastoma, mechanisms of therapeutic antibody inhibition, and the role of membrane lipids in RTK activation. She collaborates extensively with labs in Pharmacology and Cell Biology to advance interdisciplinary studies of membrane protein complexes.
Key affiliations include the Yale Cancer Center, Yale Combined Program in the Biological and Biomedical Sciences (BBS), and the Biochemistry, Quantitative Biology, Biophysics, and Structural Biology (BQBS) program. Her lab, part of the Lemmon & Ferguson Laboratories, is located at the Yale Cancer Biology Institute on West Campus, with an academic office in Sterling Hall of Medicine in New Haven.